Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
April 17, 2024 01:15 ET
|
Novartis Pharma AG
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis...
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
April 15, 2024 14:00 ET
|
Novartis Pharma AG
APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare...
Novartis tender offer for MorphoSys AG commences
April 11, 2024 04:20 ET
|
Novartis Pharma AG
Basel, April 11, 2024 – Novartis published today the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG...
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
April 06, 2024 16:16 ET
|
Novartis Pharma AG
V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant...
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
March 22, 2024 07:22 ET
|
Novartis Pharma AG
Positive CHMP opinion based on robust Phase III data, including APPLY-PNH, demonstrating superior hemoglobin improvement in the absence of transfusions with Fabhalta compared to anti-C5 therapy1-5 If...
Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
March 05, 2024 09:22 ET
|
Novartis Pharma AG
Die Aktionärinnen und Aktionäre genehmigten die 27. Dividendenerhöhung in Folge auf CHF 3,30 (+3,1 %) pro Aktie für 2023. Dies entspricht einer Rendite von 3,7%1 und einer Ausschüttung von rund 58%...
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
March 05, 2024 09:22 ET
|
Novartis Pharma AG
Les actionnaires approuvent la 27e augmentation consécutive du dividende qui passe à CHF 3,30 (+3,1%) par action pour 2023 ; représentant un rendement de 3,7%1 et une distribution du free cash-flow...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
March 05, 2024 09:22 ET
|
Novartis Pharma AG
Shareholders approve 27th consecutive dividend increase to CHF 3.30 (+3.1%) per share for 2023; representing a 3.7% yield1 and approximately 58% payout of free cash flowShareholders confirm Joerg...
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
March 04, 2024 01:15 ET
|
Novartis Pharma AG
The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the children treated in previous clinical studies...
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
February 05, 2024 16:45 ET
|
Novartis Pharma AG
Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or...